Blog
FDA Launches the Digital Health Center of Excellence
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
This white paper focuses on six key global market access trends and provides payer perspectives on these trends.
Available On Demand
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Published September 22, 2020
Executive Summary Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas. Geographic Scope: Client Situation The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making. Trinity’s Solution Trinity conducted comprehensive secondary research in the following areas: Disease background including diagnosis, prognosis, epidemiology and unmet needsCurrent and future paradigm including lines of therapies and standard of carePipeline analysis including key therapies in development and future treatment gamechangersPricing and access landscape including pricing analysis, health…
Published August 25, 2020
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…
Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making. Geographic Scope: Client Situation The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making. Trinity’s Solution Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.…
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan. Geographic Scope: Client Situation: The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks. Trinity’s Solution: Trinity conducted targeted secondary research to determine the existing mNSCLC…
Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries. Geographic Scope: Client Situation: The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars. Trinity’s Solution Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses,…
Trinity completed a detailed analogue assessment to understand how various stakeholders are involved in shaping health policies across markets. Geographic Scope: Client Situation The client wanted to identify best practices as well as the external stakeholders they should consider working with to efficiently shape global bone health policy. Trinity’s Solution Trinity conducted a systematic analogue disease area filtration to understand the disease areas where health policy development is most comparable to the bone health space. Trinity then conducted exhaustive secondary research within each analogue disease area to understand the…
Companies throughout the life sciences industry are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making. Publication Access Form…
Published July 14, 2020
Executive Summary Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake Payers are still at very different stages in their acceptance of DTx, and in contrast with traditional pharmaceuticals, buy-in from senior leadership will be an essential part of the top-down decision-making process for DTx prioritization Pharmacy benefit managers (PBMs) have taken a leadership role in facilitating a pathway for digital therapeutics adoption, and they are likely to…
By signing up, you are agreeing to our Privacy Policy.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.